BioAesthetics Corporation has appointed Dr. Juliana Blum, PhD, as its new Chief Executive Officer, starting August 12, 2024.
Dr. Sandra Coufal, MD, Director of BioAesthetics and CEO of Toragen, Inc., remarked, “This is a significant milestone for BioAesthetics. As biotech companies evolve, there comes a time when a new CEO with specialized skills is needed for further product advancement and commercialization. Dr. Blum’s experience with innovative products from her time at Humacyte will be invaluable in guiding BioAesthetics forward.”
Dr. Blum brings two decades of experience from Humacyte (NASDAQ: HUMA), where she was Co-founder and EVP of Corporate Development. She led the creation and execution of Humacyte’s commercial-scale vascular bioengineering platform and transitioned the company to a public entity. Her expertise spans R&D, global regulatory affairs, manufacturing scale-up, corporate development, and strategic partnerships. Since leaving Humacyte in late 2022, she has worked as an executive strategist and Entrepreneur in Residence at the North Carolina Biotechnology Center, advancing innovations in regenerative medicine and biotherapeutics.
“I am excited to join BioAesthetics at this pivotal moment,” Dr. Blum said. “I look forward to advancing the next-generation drug-eluting graft technology for soft tissue reconstruction and leading the ongoing clinical evaluations of our NACgraft for breast reconstruction. The team has laid a solid foundation, and I am eager to drive future growth and innovation.”
Joseph Nixon, MBA, Director of BioAesthetics and CFO of Locus Biosciences, Inc., added, “Dr. Blum’s proven track record in managing key partnerships and guiding companies from discovery to commercial launch will be crucial for BioAesthetics’ future growth.”
About BioAesthetics:
BioAesthetics Corporation is dedicated to advancing biomaterials to improve lives. Its flagship product, the NACgraft™ biologic matrix, is an acellular tissue graft for nipple regeneration in breast cancer patients undergoing reconstruction. FDA-registered and currently in clinical studies, NACgraft is part of BioAesthetics’ broader pipeline, which includes acellular regenerative grafts for wound and reconstructive care. Founded as a spin-out of Tulane University, BioAesthetics is now based in Durham, NC.
